In the Initial Article we had pointed out that the receivables from Abott Labs for Piramal was about 4, 000 crores as of Nov 2012.
Discounting for 2013 and 2014, the present value of the receivables is about 3,400 crores or about 194 a share.
This accounts for about 24% of the enterprise value.
No discussion of this deal is complete without an analysis of the transaction with Abbott labs. We will do several posts on the same. The multiples were eye-popping though the transaction (slump sale) was questioned by some. We will address and point to work done by others on the same.
The Vodafone investment along with the Abbott receivables account for over 70% of the enterprise value. In the next half a dozen articles, we will examine the DRG acquisition, the CRAMS business, OTC and Critical Care business, PHL finance and also the superior management you are getting for your money.
Discounting for 2013 and 2014, the present value of the receivables is about 3,400 crores or about 194 a share.
This accounts for about 24% of the enterprise value.
No discussion of this deal is complete without an analysis of the transaction with Abbott labs. We will do several posts on the same. The multiples were eye-popping though the transaction (slump sale) was questioned by some. We will address and point to work done by others on the same.
The Vodafone investment along with the Abbott receivables account for over 70% of the enterprise value. In the next half a dozen articles, we will examine the DRG acquisition, the CRAMS business, OTC and Critical Care business, PHL finance and also the superior management you are getting for your money.
No comments:
Post a Comment